China Science & Technology Incubation Attends the 7th VB100 Future Healthcare Summit 2023 and Co-hosts the Synthetic Biology Innovation Forum
Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global shifts and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic arrangements outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “remain steadfast despite myriad trials,” and embodying the spirit to “press forward in the face of greater adversity,” can innovators in the healthcare sector bolster their confidence through decisive action, thereby delivering a commendable response to the era’s call for high-quality development in healthcare.
The 7th Future Healthcare 100 ConferenceThemed “No Matter West or East,” and hosted by VCBeat VB100 and Eggshell Research Institute, with strategic cooperation from Shanghai Zhangjiang Group, the event integrated cutting-edge academic and research insights, comprehensive industry perspectives, and keen capital trend analysis. Held from May 5 to 7, 2023, at the Zhangjiang Science Hall in Shanghai, it brought together industry peers to explore the innovative future of the broader health sector and embark on a new journey in medical innovation.
Having been held for six editions, the conference has become China’s largest and most information-rich ecosystem event integrating industry and capital within the healthcare innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the future of tech, and focusing on venture capital interaction,” it sets the trend for innovation and investment in China’s healthcare field. The 7th Future Healthcare Top 100 Conference in 2023 will feature three major summits, over 20 thematic forums covering specialized sectors, the release of the Future Healthcare Top 100 series rankings and awards, more than ten series reports, and seven concurrent networking events. Distinguished guests and attendees—including government agencies, academicians and scientists, clinical and research experts, Fortune 500/listed companies, top-tier investment institutions/securities firms, and innovative healthcare enterprises—will be invited to participate. This gathering of minds aims to provide insights to the industry and usher in a new future.
Synthetic biology is an emerging, cutting-edge interdisciplinary field within the life sciences and a paradigmatic convergent technology. By integrating engineering principles with life science fundamentals and multidisciplinary enabling technologies, it designs and synthesizes novel or modified natural biological systems to elucidate the laws of life and construct next-generation engineered biological systems. It is hailed as “the key to understanding life” and “a disruptive technology that will change the future.”
From May 5 to 7, 2023, at the 7th Future Healthcare Top 100 Conference, Zhongke Yucheng, in collaboration with VCBeat VB100, hosted the Forum on Innovative Development of the Synthetic Biology Industry. The forum brought together experts to discuss synthetic biology technologies, industrial applications, development trends, and investment strategies in China, providing a platform for industry exchange and knowledge sharing to foster technological innovation and synergistic development across the synthetic biology supply chain in the healthcare sector.
Zhongke YuchengYou Are Invited to Attend In PersonForum on Innovative Development of the Synthetic Biology IndustryLet us jointly propel China's synthetic biology industry toward higher quality, greater sophistication, and advanced standards!
Conference Time:
May 5–7, 2023
Forum on the Innovative Development of the Synthetic Biology IndustryTime:
May 6, 2023
Conference Venue:
Shanghai Zhangjiang Science Hall (No. 1393 Haike Road, Pudong New Area, Shanghai)
Conference Registration:
(General Admission Pass, Access to 30+ Forums)
Zhongke Yucheng (Tianjin) Technology Development Co., Ltd. is a wholly-owned platform company of the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences. Located in the Binhai New Area of Tianjin, it owns the independent brand “BIOINN,” a specialized biotechnology mass innovation space.
“BIOINN” is anchored in the core philosophy of “Innovation · Creation · Life,” focusing on exceptional scientific innovators. Adhering to the principles of “market-oriented and pain-point-driven approaches, technological innovation, and platform innovation,” it integrates the “space chain, technology chain, industry chain, capital chain, and ecosystem chain.” Dedicated to the commercialization of synthetic biology and related technologies, enterprise incubation, and industrial clustering, BIOINN aims to establish a hub for the convergence of technology, information, and capital resources. By providing integrated solutions, it reduces burdens, empowers, and accelerates growth for various project-based enterprises, facilitating the practical application of cutting-edge technological achievements and driving leapfrog development in the industrial economy. To date, it has gathered over 100 domestic and international project enterprises, with a cumulative valuation exceeding RMB 10 billion.